Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test
试验速览
- 阶段
- 不适用
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Recurrence Score variation after neoadjuvant chemotherapy
研究概览
简要总结
This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the technical analysis of Mammaprint in patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in tumor tissues and evaluated the accuracy and sensitivity of Mammaprint test in the efficacy of neoadjuvant chemotherapy.A new model for predicting NCT effect of breast cancer with combined risk genes and clinical parameters was established based on the clinical characteristic parameters of patients to study the accuracy and sensitivity of Mammaprint monitoring for prognosis determination of breast cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 25 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed new breast cancer (invasive cancer)
- •Clinical stage II-III
- •Aged 25-80
- •At least 6 months of follow-up data, clinical diagnosis and treatment information and personal information available for follow-up are complete
- •Complete biological samples required for the study: fresh/frozen tissues/white tablets/wax blocks meeting the requirements of the experiment (before neoadjuvant chemotherapy)
- •Tumor markers and imaging data were complete
- •Neoadjuvant chemotherapy is commonly recommended by the standard NCCN guidelines
排除标准
- •Subjects refuse to participate
- •First diagnosis of stage I or IV breast cancer
- •Pathological diagnosis of concurrent (or previous) other malignant tumors
- •Prehistory breast cancer
- •Younger than 25 or older than 80
- •Clinical diagnosis and treatment information or biological samples required by the research institute do not meet the needs of the experiment
结局指标
主要结局
Recurrence Score variation after neoadjuvant chemotherapy
时间窗: 6 months
The recurrence score of each subtype
次要结局
未报告次要终点